Novel approaches and clinical opportunity for gastrointestinal prokinetic drugs

Drug Discovery Today: Therapeutic Strategies

Volumn 4, Issue 3, 2007, Pages 165-170

  Borman, Richard A ^a   Sanger, Gareth J ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMCINAL; AT 7505; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CISAPRIDE; DIGESTIVE TRACT AGENT; DOMPERIDONE; ERYTHROMYCIN; GASTROINTESTINAL AGENT; GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONIST; GUANYLATE CYCLASE C RECEPTOR AGONIST; KOS 2187; LINACLOTIDE; LUBIPROSTONE; MD 1100; METOCLOPRAMIDE; MITEMCINAL; MOTILIN RECEPTOR AGONIST; PROKINETIC AGENT; SEROTONIN 4 AGONIST; TD 5108; TEGASEROD;

BEDTIME DOSAGE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; ENTERITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MOTILITY; HUMAN; INTESTINE TRANSIT TIME; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; NAUSEA; NONHUMAN; REPEATED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; STOMACH EMPTYING; STOMACH PARESIS; UNSPECIFIED SIDE EFFECT;

EID: 45249107778     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2007.11.001     Document Type: Review

References (42)

1. Maier I., and Wu G.Y. Prokinetic therapy for gastroenterological diseases. Chinese J. Dig. Dis. 4 (2003) 151-159
2. Karamanolis J., and Tack J. Promotility medications - Now and in the future. Dig. Dis. 24 (2006) 297-307
3. Bassil A., et al. Prokineticin-2, motilin, ghrelin and metoclopramide: prokinetic utility in mouse stomach and colon. Eur. J. Pharmacol. 524 (2005) 138-144
4. 4 receptor agonists enhance both cholinergic and nitrergic activity in human isolated colon circular muscle. Neurogastro. Motil. 18 (2006) 853-861
5. 4 receptor in the secretory response of human small intestine to 5-HT. Br. J. Pharmacol. 110 (1993) 927-928
6. Rampe D., et al. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett. 417 (1997) 28-32
7. http://www.fda.gov/cder/drug/advisory/tegaserod.htm.
8. 2B receptor antagonist in vitro and in vivo. Br. J. Pharmacol. 143 (2004) 549-560
9. Peeters T.L. New motilin agonists: a long and winding road. Neurogastroenterol. Motil. 18 (2006) 1-5
10. Dass N.B., et al. The rabbit motilin receptor: molecular characterisation and pharmacology. Br. J. Pharmacol. 140 (2003) 948-954
11. Takeshita E., et al. Molecular characterisation and distribution of motilin family receptors in the human gastrointestinal tract. J. Gastroenterol. 41 (2006) 223-230
12. Jarvie E.M., et al. Differences between the abilities of tegaserod and motilin receptor agonists to stimulate gastric motility in vitro. Br. J. Pharmacol. 150 (2007) 455-462
13. Coulie B., et al. Involvement of two different pathways in the motor effects of erythromycin on the gastric antrum in humans. Gut 43 (1998) 395-400
14. Cuomo R., et al. Influence of motilin on gastric fundus tone and on meal-induced satiety in man: role of cholinergic pathways. Am. J. Gastroenterol. 101 (2006) 804-811
15. Richards R.D., et al. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am. J. Gastroenterol. 88 (1993) 203-207
16. Dhir R., and Richter J.E. Erythromycin in the short- and long-term control of dyspepsia symptoms in patients with gastroparesis. J. Clin. Gastroenterol. 38 (2004) 237-242
17. Dibaise J.K., and Quigley E.M. Efficacy of prolonged administration of intravenous erythromycin in an ambulatory setting as treatment of severe gastroparesis: one centre's experience. J. Clin. Gastroenterol. 28 (1999) 131-134
18. McCallum R.W., et al. Efficacy of mitemcinal, a motilin agonist, on gastrointestinal symptoms in patients with symptoms suggesting diabetic gastropathy: a randomized, multi-center, placebo-controlled trial. Alim. Pharmacol. Ther. 26 (2007) 107-116
19. Tack J., and Peeters T. What comes after macrolides and other motilin stimulants?. Gut 49 (2001) 317-318
20. Nieuwenhuijs V.B., et al. The effects of ABT-229 and octreotide on interdigestive small bowel motility, bacterial overgrowth and bacterial translocation in rats. Eur. J. Clin. Invest. 29 (1999) 33-40
21. Leite-Moreira A.F., and Soares J.-B. Physiological, pathophysiological and potential therapeutic roles of ghrelin. Drug Discov Today 12 (2007) 276-288
22. Binn M., et al. Ghrelin gastroprokinetic action in patients with neurogenic gastroparesis. Peptides 27 (2006) 1603-1606
23. Murray C.D., et al. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut 54 (2005) 1693-1698
24. Tack J., et al. Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. Alim. Pharmacol. Ther. 22 (2005) 847-853
25. le Roux C.W., et al. Ghrelin does not stimulate food intake in patients with surgical procedures involving vagotomy. J. Clin. Endocrinol. Metabol. 90 (2005) 4521-4524
26. Banks W.A., et al. Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure. J. Pharmacol. Exp. Ther. 302 (2002) 822-827
27. Shimizu Y., et al. Evidence that stimulation of ghrelin receptors in the spinal cord initiates propulsive activity in the colon of the rat. J. Physiol. 576 1 (2006) 329-338
28. Nishizawa T., et al. Enhanced plasma ghrelin levels in patients with functional dyspepsia. Alim. Pharmacol. Ther. 24 Suppl. 4 (2006) 104-110
29. De Winter B.Y., et al. Effect of ghrelin and growth hormone-releasing peptide 6 on septic ileus in mice. Neurogastroenterol. Motil. 16 (2004) 439-446
30. Liu Y.-L., et al. Ghrelin alleviates cancer chemotherapy-associated dyspepsia in mice. Cancer Chemotherap. Pharmacol. 58 (2006) 326-333
31. Rudd J.A., et al. Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin. Neurosci. Lett. 392 (2006) 79-83
32. Vestergaard E.T., et al. Constant intravenous ghrelin infusion in healthy young men: clinical pharmacokinetics and metabolic effects. Am. J. Physiol. 292 (2007) E1829-E1836
33. Neary N.M., et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 89 (1994) 2832-2836
34. Krause G., et al. Distribution of membrane bound guanylyl cyclases in human intestine. Gut 35 (1994) 1250-1257
35. Forte L.R. Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology. Regul. Pept. 81 (1999) 25-39
36. Nakazato M. Guanylin family: new intestinal peptides regulating electrolyte and water homeostasis. J. Gastroenterol. 36 (2001) 219-225
37. Giannella R.A., and Mann E.A. E. coli heat-stable enterotoxin and guanylyl cyclase C: new functions and unsuspected actions. Trans. Am. Clin. Climatol. Assoc. 114 (2003) 67-85
38. Andresen, V. et al. (2007) Effects of a novel, first-in-class guanylate cyclase-C activator, linaclotide acetate (MD-1100), on gastrointestinal and clonic transit and bowel habits in patients with constipation-predominant irritable bowel syndrome (c-IBS). Digestive Disease Week, 19-24 May 2007, Washington, USA, (Abstract 532)
39. Drossman, D.A. et al. (2007) Lubiprostone significantly improves symptom relief rates in adults with irritable bowel syndrome and constipation (IBS-C): date from two, twelve-week, randomized, placebo-controlled, double-blind trials. Digestive Disease Week, 19-24 May 2007, Washington, USA, (Abstract S2136)
40. Ambizas E.M., and Ginzburg R. Lubiprostone: a chloride channel activator for treatment of chronic constipation. Annu. Pharmacother. 41 (2007) 957-964
41. McKeage K., et al. Lubiprostone. Drugs 66 (2006) 873-879
42. Bassil, A.K. et al. (2007) Effect of lubiprostone on rat and human colon muscle; possible involvement of prostaglandin EP receptors. Digestive Disease Week, 19-24 May 2007, Washington, USA, (Abstract M2123)